Notably, combined knockdown of PSAT1 with exogenous serine intake inhibition synergistically suppressed NSCLC progression.<h4>Conclusion</h4>Collectively, our findings highlight that PSAT1 serves as a biomarker for metabolic reprogramming in NSCLC and exhibits a close association with disease development and treatment. This evidence concerns the gene PSAT1 and non-small cell lung carcinoma.